November 18th 2024
The ECLIPSE trial, a pivotal, phase 3, multi-center, open-label, randomized clinical study, has met its primary end point in metastatic castration-resistant prostate cancer.
November 15th 2024
Examining the NCCN Recommendations for Genetic Testing in Prostate Cancer
November 12th 2019In an interview with Targeted Oncology during the 2019 Prostate Cancer Consensus Conference, James L. Mohler, MD, explained the reasons for changes to the NCCN guidelines on genetic testing and counseling in prostate cancer. He also discussed what needs to be addressed in the future to further increase knowledge of genetic testing and improve its use.
Read More
Evaluating Significance of ENZAMET Trial in Metastatic Hormone-Sensitive Prostate Cancer
November 12th 2019William K. Oh, MD, discusses the rationale for presenting the data for the phase III ENZAMET trial in a plenary session at the 2019 ASCO Annual Meeting. He says these data were significant because it was a large randomized clinical trial for the treatment of newly diagnosed patients with metastatic hormone-sensitive prostate cancer.
Watch
Apalutamide With ADT Sustains QoL in Metastatic Castration-Sensitive Prostate Cancer
November 12th 2019Apalutamide plus androgen deprivation therapy maintained health-related quality of life in patients with metastatic castration-sensitive prostate cancer in addition to showing positive overall survival and radiographic progression-free survival outcomes in the phase III TITAN trial, said Neeraj Agarwal, MD.
Read More
Expert Discusses Data From First Positive Trial for PARP Inhibitor in Prostate Cancer
November 6th 2019In an interview with Targeted Oncology, Alan Bryce, MD, discussed the significance of the data from PROfound for men with mCRPC. He also highlighted findings from the CARD trial and where the field is headed in terms of targeted therapies versus chemotherapies.
Read More
A Look Back at FDA News from October 2019
November 1st 2019In October 2019, the FDA approved a new treatment option for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer, as well as a new dosing regimen for patients receiving moderately emetogenic chemotherapy. Additionally, the FDA granted breakthrough therapy designations to 2 therapies, as well as an orphan drug designation, a priority review, and 2 fast track designations.
Read More
Survey Shows Growing Use of Genetic Testing in Prostate Cancer Management in the Community
October 28th 2019In an interview with Targeted Oncology, Raoul S. Concepcion, MD, discussed the existing challenges with implementing genetic testing and genetic counseling in community practices and how they can potentially be addressed.
Read More
FDA Approves New Aprepitant Dosing Regimen for CINV After MEC
October 23rd 2019The FDA has approved a supplemental New Drug Application for a single dose of aprepitant injectable emulsion for intravenous use in patients receiving moderately emetogenic chemotherapy. The approval expands the dose for aprepitant to include a 130 mg single-dose regimen for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.<br />
Read More
Targeting DNA Repair Defects With Olaparib Improves rPFS in mCRPC
October 15th 2019In an interview with Targeted Oncology, Maha Hussain, MD, discussed targeting DNA repair defects in metastatic castration-resistant prostate cancer with the PARP inhibitor olaparib in the phase III PROfound trial.
Read More
Experts in Oncology Highlight Key Abstracts Presented at the 2019 ESMO Congress
October 7th 2019Following the 2019 ESMO Congress, experts across various fields highlighted some next steps and how these treatment options will improve the treatment landscape for patients with ovarian, lung, breast, GI, or GU cancers. Overall, the abstracts presented at this year’s meeting will change the treatment paradigm in a number of patient populations.
Read More
Annual Meeting Continues Moving Personalized Medicine to the Fore
October 7th 2019The introduction of<strong> </strong>CDK4/6 inhibitors for the treatment of hormone receptor–positive, HER2-negative breast cancer has transformed therapy management and extended survival for this patient population. The next step in the process of tailoring therapy towards individual patients is the introduction of targeted therapies for patient subsets with driver aberrations.
Read More
ASCO Adds Oral Anticoagulants to Venous Thromboembolism Guidelines for Patients With Cancer
October 4th 2019The addition of direct oral oral anticoagulants for the management of venous thromboembolism in patients with cancer is the latest change to previous guidelines issued by the American Society of Clinical Oncology.
Read More
FDA Grants Breakthrough Designation to Niraparib for Metastatic CRPC
October 4th 2019The FDA has granted a breakthrough therapy designation to niraparib for the treatment of patients with <em>BRCA1/2</em>-mutated metastatic castration-resistant prostate cancer who have previously received taxane chemotherapy and androgen receptor–targeted therapy.
Read More
Clinically Meaningful Improvement in TRK Fusion Cancer Detected with Larotrectinib
October 3rd 2019Using a measure known as the growth modulation index, patients with TRK fusion–positive cancers who were treated with larotrectinib had a clinically meaningful improvement in progression-free survival compared with the time to progression on their prior treatment, an analysis of patients enrolled in 1 of 3 clinical trials has found.
Read More
A Look Back at FDA News from September 2019
October 1st 2019In September 2019, the FDA approved new treatment options for patients with endometrial carcinoma, prostate cancer, and multiple myeloma. The FDA also expanded the indication for the Cologuard noninvasive screening test for colorectal cancer. During the month there were 2 breakthrough therapy designations, 2 fast track designations, 1 orphan drug designation, and 1 priority review granted.
Read More
Olaparib Improves rPFS in Heavily Pretreated HRR+ mCRPC
September 30th 2019In the phase III PROfound trial, olaparib improved radiographic progression-free survival compared to either abiraterone acetate or enzalutamide in men with heavily pretreated metastatic castration-resistant prostate cancer, who had homologous recombination repair gene alterations, according to findings presented at the 2019 ESMO Congress.
Read More
Larotrectinib Maintains Safety and High Efficacy in TRK Fusion-Positive Cancer
September 29th 2019Three clinical trials presented at the 2019 ESMO Congress show that the tropomyosin receptor kinase inhibitor larotrectinib continues to show anti-tumor activity, including long-lasting objective responses and low toxicity, according to results from an integrated analysis.
Read More
Trend in OS Benefit Seen With Apalutamide in SPARTAN Trial for Nonmetastatic CRPC
September 27th 2019In the phase III SPARTAN trial, the combination of androgen receptor apalutamide and androgen deprivation therapy led to an overall survival OS benefit compared with placebo/androgen deprivation therapy in patients with nonmetastatic castration-resistant prostate cancer, based on the updated findings presented at the 2019 ESMO Congress.
Read More
Expert Discusses Safety Profile from the ENZAMET Trial
September 27th 2019Christopher Sweeney, MBBS, professor of medicine, Harvard Medical School, and physician, Dana-Farber Cancer Institute, discusses the treatment-related adverse events associated with adding enzalutamide or non-steroidal anti-androgens to testosterone suppression treatment and docetaxel in patients with metastatic hormone-sensitive prostate cancer, as seen in the ENZAMET trial.<br />
Watch